Fig. 5: Preclinical validation of pre-TCR therapeutic targeting for T-ALL treatment.
From: Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia
a,d, Schematic design of in vivo experimental treatment of human T-ALL with an anti-pTα monoclonal antibody. Sublethally irradiated SCID (a) or NSG mice (d) were subjected to i.v. injection with T-ALL3 (b; 106 cells per mouse) or T-ALL42 (e; 2 × 106 cells per mouse) samples, respectively, recovered from spleen xenografts of NSG mice. Mice were serially i.p. injected (twice weekly for 3–10 weeks) with either anti-pTα monoclonal antibody or isotype-matched control (IgG2a, 10 mg per kg body weight), starting at week 3-4 after transplant, when T-ALL engraftment in peripheral blood was >1%. b,e, Percentages of T-ALL3 (b) and T-ALL42 (e) cells infiltrating the peripheral blood of mice at the indicated days after transplant, upon treatment with anti-pTα monoclonal antibody or IgG2a control. Data from one experiment are shown as the mean ± s.e.m. cell percentages from control (n = 7) or anti-pTα-treated (n = 8) mice in b, ****P < 0.0001; or from control, or anti-pTα-treated or VxL-treated mice (n = 7 per group) in e, analyzed by a mixed-effects model (REML). c, Kaplan–Meier survival curves of mice in b were compared using a log-rank Mantel–Cox test. ***P = 0.0006).
